RxDoctor Payments Data

Yi Zhang, MD

Neurological Surgery · Honolulu, HINPI 1083666978

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $455,948 of the $757,532 with a category attached, or 60.2%. Microvention, Inc. accounts for 94.3% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $152,883 and has fallen 57.5% since, to $64,927 in 2025.

$757,532in general payments, 2019–2025

Across 783 payments — averaging $967.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Microvention, Inc.$715K
  • Stryker$22K
  • Medical Device Business Services, Inc.$11K
  • Silk Road Medical, Inc.$2K
  • Johnson & Johnson$2K
  • Medtronic$2K
  • plus $5K from 19 others
$246,720in research payments, 2019–2025

Across 35 payments — averaging $7049.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Microvention, Inc.$247K

What the payments were for

  • Consulting fees$135,27818%
  • Speaking & faculty fees$455,94860%
  • Travel & lodging$145,03119%
  • Food & beverage$20,6803%
  • Education$5950%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neurological surgery providers in Hawaiito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$204,545
Medicare patients
111
Services billed
733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor33$23,679

Paid to pharmacies, not to this prescriber.

Other neurological surgery in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →